Some drugs can cause taste disturbances
... Antineoplastics (drugs used for cancer or rheumatoid arthritis such as cyclophosphamide, methotrexate, etc) also lead to taste changes by affecting cell turnover. Antithyroid drugs (methimazole, propylthiouracil, etc) can decrease taste sensation...by binding zinc. Hypothyroidism can also lead to ta ...
... Antineoplastics (drugs used for cancer or rheumatoid arthritis such as cyclophosphamide, methotrexate, etc) also lead to taste changes by affecting cell turnover. Antithyroid drugs (methimazole, propylthiouracil, etc) can decrease taste sensation...by binding zinc. Hypothyroidism can also lead to ta ...
- Journal of Stroke and Cerebrovascular Diseases
... major differences between the ICTUS and the previous trials are displayed in Figure 3. The results of the ICTUS, thus, seem valid and almost doubles the available results of the effect of citicoline in AIS. Davalos et al29 have set a high standard of quality in the planning, conduction, and presenta ...
... major differences between the ICTUS and the previous trials are displayed in Figure 3. The results of the ICTUS, thus, seem valid and almost doubles the available results of the effect of citicoline in AIS. Davalos et al29 have set a high standard of quality in the planning, conduction, and presenta ...
Pharmacy and Pharmaceutical Sciences
... VCE: 30 in English (ESL) or 25 in any other English, and 25 in chemistry, and 25 in mathematical methods (CAS) or specialist mathematics. IB: 4 in English SL or 3 in English HL or 5 in English B SL or 4 in English B HL, and 4 in chemistry SL or 3 in chemistry HL, and 4 in mathematics SL or 3 in ...
... VCE: 30 in English (ESL) or 25 in any other English, and 25 in chemistry, and 25 in mathematical methods (CAS) or specialist mathematics. IB: 4 in English SL or 3 in English HL or 5 in English B SL or 4 in English B HL, and 4 in chemistry SL or 3 in chemistry HL, and 4 in mathematics SL or 3 in ...
Apo-Amoxycillin Capsules
... Animal studies with amoxycillin have shown no teratogenic effects. Amoxycillin has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. Amoxycillin may be used in pregnancy when the potential benefits outweigh the potential ri ...
... Animal studies with amoxycillin have shown no teratogenic effects. Amoxycillin has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. Amoxycillin may be used in pregnancy when the potential benefits outweigh the potential ri ...
Drug-Associated Disease: Cytochrome P450 Interactions
... number of clinically important interactions to 25 through careful evaluation of the literature and ratings by an expert panel using a modified Delphi process [60]. The correlation of four common drug interaction compendia on interaction or severity also was evaluated during the study [61]. Drug inte ...
... number of clinically important interactions to 25 through careful evaluation of the literature and ratings by an expert panel using a modified Delphi process [60]. The correlation of four common drug interaction compendia on interaction or severity also was evaluated during the study [61]. Drug inte ...
Pharmacokinetic (PK) study design for establishing bioequivalence
... – Product is in the WHO list – Approval in an ICH – Associate Country- Pre-qualified by WHO – Extensive documented use in clinical trials reported in peer-reviewed scientific journals – Long unproblematic post-market surveillance (“well selected comparator”) ...
... – Product is in the WHO list – Approval in an ICH – Associate Country- Pre-qualified by WHO – Extensive documented use in clinical trials reported in peer-reviewed scientific journals – Long unproblematic post-market surveillance (“well selected comparator”) ...
Gregory W. Albers, Sven Jacobson, J. Marc Simard and Barney J
... treated with oral sulfonylureas.8 The proportion of subjects with 90-day modified Rankin Scale ≤4 was 90% compared with 24% (at 12 months) in patients from a pooled analysis of decompressive craniectomy trials.9 This pilot study has shortcomings. It was open-label, had no placebo control arm, and th ...
... treated with oral sulfonylureas.8 The proportion of subjects with 90-day modified Rankin Scale ≤4 was 90% compared with 24% (at 12 months) in patients from a pooled analysis of decompressive craniectomy trials.9 This pilot study has shortcomings. It was open-label, had no placebo control arm, and th ...
Opiates and Respiratory Depression - index
... when the machine is expecting a 1 mg/mL concentration, or acceptance of the default (initial) drug concentration when the correct action is to scroll up to the correct value, among other errors. In 1997, ECRI documented 3 deaths that occurred while patients were connected to the Lifecare 4100.5 In a ...
... when the machine is expecting a 1 mg/mL concentration, or acceptance of the default (initial) drug concentration when the correct action is to scroll up to the correct value, among other errors. In 1997, ECRI documented 3 deaths that occurred while patients were connected to the Lifecare 4100.5 In a ...
Treatment Form
... QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, ...
... QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, ...
Like Zolpidem, all sleeping pills and anti
... prolonged, the body is increasingly tired. In order to cope and maintain a stable physical and psychological condition, the subjects are forced to indefinitely increase the doses. Therefore, as I have just pointed out, all benzodiazepines (Lexomil, Temesta, and their generic equivalents, etc.) and r ...
... prolonged, the body is increasingly tired. In order to cope and maintain a stable physical and psychological condition, the subjects are forced to indefinitely increase the doses. Therefore, as I have just pointed out, all benzodiazepines (Lexomil, Temesta, and their generic equivalents, etc.) and r ...
development and validation of rp
... high performance liquid chromatographic (RP-HPLC) method for estimation of cinitapride hydrogen tartarate a new prokinetic drug, and anti ulcer agent of the benzamide class It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors in raw material and pharmace ...
... high performance liquid chromatographic (RP-HPLC) method for estimation of cinitapride hydrogen tartarate a new prokinetic drug, and anti ulcer agent of the benzamide class It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors in raw material and pharmace ...
Praluent - Sanofi
... alirocumab was dosed at up to 75 mg/kg/dose by the subcutaneous route on gestation days 6 and 12 at exposures 12-fold the maximum recommended human dose of 150 mg every two weeks, based on serum AUC. In cynomolgus monkeys, suppression of the humoral immune response to keyhole limpet hemocyanin (KLH) ...
... alirocumab was dosed at up to 75 mg/kg/dose by the subcutaneous route on gestation days 6 and 12 at exposures 12-fold the maximum recommended human dose of 150 mg every two weeks, based on serum AUC. In cynomolgus monkeys, suppression of the humoral immune response to keyhole limpet hemocyanin (KLH) ...
Guideline on clinical investigation of medicinal products in the
... for which the drug is intended. Studies for the evaluation of efficacy or safety of a new antihypertensive drug are mainly performed in patients with primary or essential hypertension of mild to moderate severity with elevated systolic and diastolic blood pressure. Patients of both genders should be ...
... for which the drug is intended. Studies for the evaluation of efficacy or safety of a new antihypertensive drug are mainly performed in patients with primary or essential hypertension of mild to moderate severity with elevated systolic and diastolic blood pressure. Patients of both genders should be ...
Herbert Barry III by Thomas A. Ban
... HB: Yes. I was a post-doctoral research fellow for two years. During that time Neal Miller applied for a research grant in psychopharmacology with me as his coinvestigator, not co-principal investigator. I became an instructor and soon afterward an assistant professor at Yale during the two more yea ...
... HB: Yes. I was a post-doctoral research fellow for two years. During that time Neal Miller applied for a research grant in psychopharmacology with me as his coinvestigator, not co-principal investigator. I became an instructor and soon afterward an assistant professor at Yale during the two more yea ...
GHS Medication Therapy Disease Management Program(MTDM)
... Studies in breast cancer patients show that adherence rates drop off the longer patients take the medication Alternatively, in a study of patients taking capecitabine (Xeloda), patients were more adherent if they were seen every cycle Just because the medication is taken at home does not mean that t ...
... Studies in breast cancer patients show that adherence rates drop off the longer patients take the medication Alternatively, in a study of patients taking capecitabine (Xeloda), patients were more adherent if they were seen every cycle Just because the medication is taken at home does not mean that t ...
Medical Marijuana: What is the therapeutic value?
... smoking-related risks) is greater than oral/other FDA-approved THCbased medications, and for which specific medical conditions • Physician recommendations for smoked MJ for any medical purpose ...
... smoking-related risks) is greater than oral/other FDA-approved THCbased medications, and for which specific medical conditions • Physician recommendations for smoked MJ for any medical purpose ...
Myonal Myonal
... Blood concentration Eperisone hydrochloride was administered orally to 8 healthy adult male volunteers at a single dose of 150 mg once daily note) for 14 consecutive days and the plasma concentration was determined on days 1, 8 and 14. The time to reach the peak plasma concentration (tmax) ranged fr ...
... Blood concentration Eperisone hydrochloride was administered orally to 8 healthy adult male volunteers at a single dose of 150 mg once daily note) for 14 consecutive days and the plasma concentration was determined on days 1, 8 and 14. The time to reach the peak plasma concentration (tmax) ranged fr ...
Permeability Enhancement Techniques for Poorly Permeable Drugs
... delivery of poorly permeable and/or highly lipophilic drugs since they can be manufactured from excipients that have solubilising or even permeation enhancing properties. Oral nano emulsions which have a droplet size of less than 150 nm, are almost from the o/w type.Similar to conventional emulsions ...
... delivery of poorly permeable and/or highly lipophilic drugs since they can be manufactured from excipients that have solubilising or even permeation enhancing properties. Oral nano emulsions which have a droplet size of less than 150 nm, are almost from the o/w type.Similar to conventional emulsions ...
Clopixol-Acuphase® 50 mg/ml Zuclopenthixol acetate
... An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other an ...
... An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other an ...
Product Monograph Template - Standard
... There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking ULORIC®, although the reports contain insufficient information necessary to establish the probable cause. During randomized controlled studies, transaminase elevations greater than three times the upper l ...
... There have been postmarketing reports of fatal and non-fatal hepatic failure in patients taking ULORIC®, although the reports contain insufficient information necessary to establish the probable cause. During randomized controlled studies, transaminase elevations greater than three times the upper l ...
Digoxin – Loading Dose Guide (Adults)
... Prescribe and administer the loading dose in 2 portions with half of the total dose given as the first portion and the second portion 6 hours later. Write “LOADING Dose” on the prescription Add dose to 50 - 100mL of Sodium chloride 0.9% or glucose 5% Administer using a rate controlled infusion pump ...
... Prescribe and administer the loading dose in 2 portions with half of the total dose given as the first portion and the second portion 6 hours later. Write “LOADING Dose” on the prescription Add dose to 50 - 100mL of Sodium chloride 0.9% or glucose 5% Administer using a rate controlled infusion pump ...
Restoril™ (temazepam) Capsules USP Rx only DESCRIPTION
... “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedativehypnotic-naïve as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep-driving may occur with R ...
... “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedativehypnotic-naïve as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep-driving may occur with R ...
Dr Swee Tan wins Medicines New Zealand Award for research The
... at the GMRI and all my colleagues in the medical and science communities who have been involved in the quest to find a better way to manage this tumour.” He said the $20,000 funding associated with the award will be used for furthering research into cancer at the GMRI, building on current work. Hon ...
... at the GMRI and all my colleagues in the medical and science communities who have been involved in the quest to find a better way to manage this tumour.” He said the $20,000 funding associated with the award will be used for furthering research into cancer at the GMRI, building on current work. Hon ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.